About us
P2PAR-100: Our Lead Product
Pattern’s lead product, P2PAR-100, is an immunotherapeutic which activates innate immune cells to kill cancer cells and safely activate an efficacious innate and adaptive immune response, thereby overcoming the limitations of many traditional therapies.
P2PAR-100 has high molar activity, is easy to store and use, and is effective when administered systemically or intralesionally in microgram amounts.
Within the next 12 months, Pattern expects to file an Investigational New Drug (IND) Application with the US FDA for P2PAR-100, in order to commence a Phase 1b/2a clinical study at MD Anderson Cancer Center (MDACC), with Phase 1a addressing advanced solid tumors in general and Part 2a addressing HPV-associated cancers.
Pattern has received pre-IND feedback from the FDA and has since then been incorporating the FDA’s feedback.
P2PAR-100: How it works
Pattern’s lead product candidate, P2PAR-100, is a TLR agonist (TLR4 in particular, but also TLR1/2 and TLR2/6). P2PAR-100 works by activating key innate immune cells including macrophages, dendritic cells (DCs) and natural killer cells. In addition, P2PAR-100 also mobilizes the adaptive immune system (via DCs) and creates protective immune memory through a process of in situ vaccination. This process occurs without any need to previously identify and isolate antigens or genetic material.
P2PAR-100 also triggers the transient production of Type I and II interferons and cytokines by immune cells (TNFα, IL-12, IFN-β, IFN-γ, IL-1α, IL-1β, GM-CSF, MCP-1, IL-27, etc.). In addition, P2PAR causes the membrane expression of costimulatory molecules (CD80, CD86, CD40) and MHCI and MHCII molecules on antigen-presenting cells, as well as the production of effector mediators such as nitric oxide and peroxynitrite.
Opportunities: Pipeline in a Product
Pattern’s initial focus is on HPV-related cancers. Despite the availability of preventive HPV vaccines, HPV prevalence remains high and HPV-associated cancers remain a significant health concern worldwide. It is estimated that 5% of all cancers worldwide (with more than 600,000 new cancer cases per year) are attributable to HPV.
Other pipeline opportunities for P2PAR-100 include cancers caused by infections in general (15%+ of cancers), as well as other cancers more generally.
Based on existing clinical and pre-clinical data, there are also combination therapy opportunities with conventional cancer therapies and/or other immunotherapies such as checkpoint inhibitors.
Collaborations
Pattern has collaborated closely with the Massachusetts General Hospital (Harvard), the National Research Council of Canada (NRC), McGill University (Goodman Cancer Centre and TB Centre), and the University of Toronto.






Pattern is open to partnerships that will move its clinical programs forward and enhance the development of our internal pipeline.
Directors and Leadership
Mark de Groot, PhD
Director and CEO
Hans Keirstead, PhD
Director
Nick Glover, PhD
Director
John Abeles, MD
Director
Andrew Williams, MBA
Chief Financial Officer
Yann Rioux, MSc
Director, Operations
Elizabeth Acosta, PhD
Director, R&D
Key Advisors and Employees
Mark Poznansky, MD, PhD
Clinical and Scientific Advisor
Frank Perabo, MD, PhD
Clinical and Scientific Advisor
Denis Bosc
CMC and Technical Advisor
Dee Mahoney
Commercial Advisor
